1 unchanged sentence
Trading Plans
−Removed: On June 4, 2025 , Todd Franklin Watanabe , our Chief Executive Officer , entered into a Rule 10b5-1 trading plan , intended to satisfy the affirmative defense of Rule 10b5-1(c) under the Exchange Act.
−Removed: The plan provided for the potential sale of up to 135,000 shares of common stock held by Mr.
−Removed: Watanabe between October 1, 2025 and September 30, 2026 .
−Removed: On June 6, 2025 , Masaru Matsuda , our General Counsel , entered into a Rule 10b5-1 trading plan , intended to satisfy the affirmative defense of Rule 10b5-1(c) under the Exchange Act.
−Removed: The plan provided for the potential sale of up to 83,126 shares of common stock held by Mr.
−Removed: Matsuda between September 4, 2025 and September 4, 2026 .
+Added: On August 14, 2025 , Neha Krishnamohan , a member of our Board of Directors, entered into a Rule 10b5-1 trading plan , intended to satisfy the affirmative defense of Rule 10b5-1(c) under the Exchange Act.
+Added: The plan provided for the potential sale of up to 1,232 shares of common stock held by Ms.
+Added: Krishnamohan, as well as the potential exercise and sale of up to 39,272 options between November 12, 2025 and November 2, 2026 .
Number Description of Document Incorporated by Reference Form Date Number Filed/Furnished Herewith
7 unchanged sentences
S-1/A 1/21/20 4.2
−Removed: Manufacturing Supply Agreement, dated as of November 8, 2023 , by and between the Registrant and Bo ra Pharmaceuticals Services Inc.
−Removed: Amendment No.
−Removed: 1 to the Manufacturing Supply Agreement, dated as of March 22 , 2024 , by and between the Registra nt and Bora Pharmaceuticals Services Inc.
−Removed: Amendment No.
−Removed: 2 to the Manufacturing Supply Agreement, dated as of May 14, 2025 , by and between the Registrant and Bora Pharmaceuticals Services Inc.
−Removed: 10.4 Severance & Change in Control Agreement, dated as of April 10, 2025, by and between the Registrant and Latha Vairavan .
−Removed: 10.5 Amended and Restated Non-Employee Director Compensation Program.
31.1 Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities and Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
15 unchanged sentences
under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, whether made before or after the date of this Form 10-Q, irrespective of any general incorporation language contained in such filing.
−Removed: Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this Quarterly Report on Form 10-Q to be signed on its behalf by the undersigned, thereunto duly authorized.
+Added: Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this Quarterly Report on Form 10-Q to be signed on its behalf by the undersigned, thereunto duly
ARCUTIS BIOTHERAPEUTICS, INC.
−Removed: August 06, 2025 By:
+Added: October 28, 2025 By:
/s/ Todd Franklin Watanabe
2 unchanged sentences
(Principal Executive Officer)
−Removed: August 06, 2025 By:
+Added: October 28, 2025 By:
/s/ Latha Vairavan
3 unchanged sentences
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.